Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis
Reumatol Clin (Engl Ed). 2018 Nov-Dec;14(6):320-333.
doi: 10.1016/j.reuma.2017.08.008.
Epub 2017 Oct 16.
[Article in
English,
Spanish]
Authors
Jordi Gratacós
1
, Petra Díaz Del Campo Fontecha
2
, Cristina Fernández-Carballido
3
, Xavier Juanola Roura
4
, Luis Francisco Linares Ferrando
5
, Eugenio de Miguel Mendieta
6
, Santiago Muñoz Fernández
7
, Jose Luis Rosales-Alexander
8
, Pedro Zarco Montejo
9
, Mercedes Guerra Rodríguez
2
, Victoria Navarro Compán
6
Affiliations
- 1 Servicio de Reumatología, Hospital Universitario Parc Taulí, I3PT, UAB, Sabadell, Barcelona, España. Electronic address: jgratacosmas@gmail.com.
- 2 Unidad de Investigación, Sociedad Española de Reumatología, Madrid, España.
- 3 Servicio de Reumatología, Hospital General Universitario de Elda, Elda, Alicante, España.
- 4 Servicio de Reumatología, Hospital Universitari Bellvitge, Hospitalet de Llobregat, Barcelona, España.
- 5 Servicio de Reumatología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, España.
- 6 Servicio de Reumatología, Hospital Universitario La Paz, IdiPaz, Madrid, España.
- 7 Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, San Sebastián de los Reyes, Madrid, España.
- 8 Servicio de Reumatología, Hospiten Rambla, Santa Cruz de Tenerife, España.
- 9 Servicio de Reumatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
Abstract
Objective:
Recent data published on biological therapy in axial spondyloarthritis (axSpA) since the last publication of the recommendations of the Spanish Society of Rheumatology (SER) has led to the generation of a review of these recommendations based on the best possible evidence. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with axSpA.
Methods:
Recommendations were drawn up following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Centre for Evidence Based Medicine at Oxford. The level of agreement was established through the Delphi technique.
Results:
In this review, we did an update of the evaluation of disease activity and treatment objectives. We included the new drugs with approved therapeutic indication for axSpA. We reviewed both the predictive factors of the therapeutic response and progression of radiographic damage. Finally, we drafted some recommendations for the treatment of patients refractory to anti-tumor necrosis factor, as well as for the possible optimization of biological therapy. The document also includes a table of recommendations and a treatment algorithm.
Conclusions:
We present an update of the SER recommendations for the use of biological therapy in patients with axSpA.
Keywords:
Axial spondyloarthritis; Biologic therapy; Espondiloartritis axial; Espondiloartritis periférica; Peripheral spondyloarthritis; Recomendaciones; Recommendations; Sociedad Española de Reumatología; Spanish Society of Rheumatology; Terapia biológica; Tratamiento; Treatment.
Copyright © 2017 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antirheumatic Agents / therapeutic use
-
Biological Therapy / methods
-
Biological Therapy / standards*
-
Delphi Technique
-
Humans
-
Spain
-
Spondylarthritis / diagnosis
-
Spondylarthritis / drug therapy*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents